Is CVS Health (CVS) Fully Valued After Its New Pharmacy Focus Rollout?

CVS Health (CVS) stock is in focus after the company opened its first pharmacy-focused CVS Pharmacy in Houston, part of a broader rollout of nearly 20 smaller, community-oriented locations nationwide.

See our latest analysis for CVS Health.

For investors tracking CVS Health, the recent pharmacy-focused expansion comes on top of strong momentum, with a 30-day share price return of 9.45%, a 90-day share price return of 39.10%, and a 1-year total shareholder return of 80.96%. This suggests that recent news is feeding into already elevated expectations around the stock.

If you are interested in how healthcare and technology intersect, this could be a useful moment to widen your search and review 39 healthcare AI stocks

CVS Health now trades close to analyst targets, yet still sits at a steep estimated discount to some intrinsic value models. Is the market being cautious for good reason after such a strong run, or mispricing the stock?

Most Popular Narrative: 10% Undervalued

Against a last close of $107.61 for CVS Health, the most followed narrative points to a fair value of $107.73, implying a small discount that still hinges on specific growth and margin assumptions.

Integration of recent and ongoing acquisitions (such as Aetna, Oak Street, and Signify Health) and vertical alignment between insurance, pharmacy, and care delivery provide substantial cross-selling and synergy opportunities, supporting long-term operating margin and earnings growth as margin recovery initiatives gain traction.

Read the complete narrative.

Want to see what kind of revenue trajectory and margin reset are baked into that view? The narrative leans on compound earnings growth and a future earnings multiple that has to compress meaningfully from today. Curious which assumptions do the heavy lifting and how sensitive that $107.73 figure is to even small changes in profitability and discount rate?

Result: Fair Value of $107.73 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, CVS Health still faces pressure from medical cost trends and reimbursement scrutiny, which could squeeze margins and challenge the earnings path implied by that narrative.

Find out about the key risks to this CVS Health narrative.

Another View: CVS Health Through a P/E Lens

The SWS DCF model presents CVS Health as deeply undervalued, yet the market is assigning a very different tag. At a P/E of 46.8x versus a Healthcare industry average of 26.1x, a peer average of 19.7x and a fair ratio of 40.7x, the stock screens as expensive on earnings. The key question is whether this premium holds up if growth or margins disappoint.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With CVS Health caught between optimism and concern, this is a good time to review the numbers yourself, weigh both sides, and see whether the balance of 1 or more potential rewards and 1 or more key risks fits your own thesis by starting with the 2 key rewards and 5 important warning signs.

Looking for more investment ideas beyond CVS Health?

Do not stop with a single stock. The best portfolios usually come from comparing multiple quality ideas side by side using clear, consistent data.

Use the Simply Wall St Screener to spot opportunities that fit your style before they move out of reach.

• Target potential bargains by scanning 45 high quality undervalued stocks that combine quality fundamentals with appealing pricing signals.
• Strengthen your income stream by reviewing 9 dividend fortresses that focus on higher-yield payouts.
• Prioritize resilience by checking 80 resilient stocks with low risk scores built around companies with lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com